COVID-19: Thoughts while circling the wagons
Contemporary Pediatrics
; 37(4):24, 2020.
Article
in English
| ProQuest Central | ID: covidwho-831157
ABSTRACT
Compared with regulatory agencies overseas, it is a very long and very expensive proposition to gain FDA approval to market a new drug or device. [...]in the United States we don't have a POC C-reactive protein (CRP) device that could help management of respiratory infections. [...]insurance companies have restricted access to better POC diagnostic studies by refusing to pay for more accurate tests when less-expensive (and less-accurate) tests are covered.
Search on Google
Collection:
Databases of international organizations
Database:
ProQuest Central
Language:
English
Journal:
Contemporary Pediatrics
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS